X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ICOone® delivers a dry powder, there is no need for expensive and complicated cold storage. Inhaling the drug eliminates the use of disposable syringes and no hazardous waste with blood contaminated syringes is generated.
Lead Product(s): Oxytocin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ICOone
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
Details:
The agreement focuses on the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.
Lead Product(s): RES030-085
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RES030-085
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.3 million Upfront Cash: Undisclosed
Deal Type: Agreement May 20, 2021
Details:
Iconovo is working on a generic Symbicort in ICOres with Amneal. The extended agreement covers 90 percent of the global Symbicort market, doubling the expected annual royalty revenue from Amneal.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ICOres
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 17, 2021
Details:
ISR will have exclusive rights to use ICOone for treating Covid-19 and its variants with a technology based on spike proteins with an adjuvant. Iconovo will develop an inhalation product for the purpose of testing it in a human clinical trial.
Lead Product(s): Adjuvanted SARS-CoV-2 spike proteins
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Immune System Regulation
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
Details:
The agreement gives Monash an exclusive global right to use ICOone with oxytocin to prevent postpartum haemorrhage in women giving birth.
Lead Product(s): Oxytocin
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ICOone
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Monash University
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration December 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
